Cash and Short Term Investments (Quarterly) Chart

View Cash and Short Term Investments (Quarterly) for LXRX.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Cash and Short Term Investments (Quarterly) Chart
Start Trial

Historical Cash and Short Term Investments (Quarterly) Data

View and export this data back to 2000. Start Trial.
Date Value
June 30, 2026 190.61M
March 31, 2026 170.66M
December 31, 2025 96.23M
September 30, 2025 115.95M
June 30, 2025 139.01M
March 31, 2025 194.84M
December 31, 2024 237.96M
September 30, 2024 258.37M
June 30, 2024 309.96M
March 31, 2024 355.60M
December 31, 2023 170.03M
September 30, 2023 218.43M
June 30, 2023 256.74M
March 31, 2023 105.94M
December 31, 2022 138.36M
September 30, 2022 136.20M
June 30, 2022 61.97M
March 31, 2022 86.50M
December 31, 2021 86.74M
September 30, 2021 120.92M
June 30, 2021 118.50M
March 31, 2021 141.36M
December 31, 2020 152.28M
September 30, 2020 111.45M
June 30, 2020 201.87M
Date Value
March 31, 2020 249.14M
December 31, 2019 271.66M
September 30, 2019 296.30M
June 30, 2019 105.98M
March 31, 2019 133.14M
December 31, 2018 160.05M
September 30, 2018 187.30M
June 30, 2018 209.69M
March 31, 2018 262.27M
December 31, 2017 310.79M
September 30, 2017 196.82M
June 30, 2017 231.19M
March 31, 2017 259.74M
December 31, 2016 346.50M
September 30, 2016 395.56M
June 30, 2016 429.36M
March 31, 2016 477.15M
December 31, 2015 521.35M
September 30, 2015 256.42M
June 30, 2015 282.48M
March 31, 2015 315.10M
December 31, 2014 339.34M
September 30, 2014 57.87M
June 30, 2014 79.04M
March 31, 2014 98.37M

Cash and Short Term Investments Definition

Represents the sum of cash and short term investments.

Read full definition.

Cash and Short Term Investments (Quarterly) Range, Past 5 Years

View Cash and Short Term Investments (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Cash and Short Term Investments (Quarterly) Benchmarks

View Cash and Short Term Investments (Quarterly) Benchmarks
Start Trial
Viatris, Inc. 1.410B
Pfizer Inc. 11.70B
ANI Pharmaceuticals, Inc. 375.87M
Corcept Therapeutics, Inc. 308.20M
Veru, Inc. 25.79M